SCHEMBL17014134

SCHEMBL17014134

CCc1cncc(Nc2cc(COc3ccc([N+](=O)[O-])c4ccccc34)ccn2)n1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
HCK P08631 5/20 0.36
MAPK12 P53778 5/20 0.36
MAPK14 Q16539 5/20 0.36
SRC P12931 2/20 0.36
CTSV O60911 2/20 0.36
CTSL P07711 2/20 0.36
PTGES O14684 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
POLB P06746 1/20 0.34
MYC P01106 1/20 0.34
MAPT P10636 3/20 0.33
KMT2A Q03164 2/20 0.33
CYP19A1 P11511 2/20 0.33
MEN1 O00255 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31086801 0.90 LMNA (0.41) ALDH1A1LMNAHCKMAPK12MAPK14
SCHEMBL17008473 0.90 LMNA (0.41) ALDH1A1LMNAHCKMAPK12MAPK14
SCHEMBL31086726 0.90 CTSV (0.39) ALDH1A1LMNAHCKMAPK12MAPK14
SCHEMBL17008509 0.90 CTSV (0.39) ALDH1A1LMNAHCKMAPK12MAPK14
SCHEMBL17008492 0.88 ALDH1A1 (0.39) ALDH1A1LMNAHCKMAPK12MAPK14
SCHEMBL31086600 0.87 LMNA (0.40) ALDH1A1LMNAHCKMAPK12MAPK14
SCHEMBL17008491 0.87 LMNA (0.40) ALDH1A1LMNAHCKMAPK12MAPK14
SCHEMBL17014136 0.85 HCK (0.37) HCKMAPK12MAPK14SRCSMN1; SMN2
SCHEMBL17017528 0.84 HCK (0.35) HCKMAPK12MAPK14SRCSMN1; SMN2
SCHEMBL31086607 0.84 HCK (0.35) HCKMAPK12MAPK14SRCSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11634406-B2 Inhibitor of p38 MAP kinase RESPIVERT LTD. (GB) 2023-04-25 US disclosed
US-20210179584-A1 INHIBITOR OF p38 MAP KINASE RESPIVERT LIMITED (GB) 2021-06-17 US disclosed
US-10815217-B2 Inhibitor of p38 MAP kinase RESPIVERT LTD. (GB) 2020-10-27 US disclosed
EP-3357919-B1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS RESPIVERT LTD (GB) 2019-11-20 EP disclosed
US-20190092752-A1 INHIBITOR OF p38 MAP KINASE TOPIVERT PHARMA LTD. (GB) 2019-03-28 US disclosed
EP-3357919-A1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS Respivert Limited (GB) 2018-08-08 EP disclosed
EP-3105222-B1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS RESPIVERT LTD (GB) 2018-04-11 EP disclosed
US-20170182039-A1 INHIBITOR OF p38 MAP KINASE TOPIVERT PHARMA LTD. (GB) 2017-06-29 US disclosed
US-20170182039-A1 INHIBITOR OF p38 MAP KINASE TOPIVERT PHARMA LTD. (GB) 2017-06-29 US disclosed
US-9624196-B2 Inhibitor of p38 MAP kinase RESPIVERT LTD. (GB) 2017-04-18 US disclosed
US-9624196-B2 Inhibitor of p38 MAP kinase RESPIVERT LTD. (GB) 2017-04-18 US disclosed
US-20160368896-A1 INHIBITOR OF p38 MAP KINASE RESPIVERT LIMITED (GB) 2016-12-22 US disclosed
US-20160368896-A1 INHIBITOR OF p38 MAP KINASE RESPIVERT LIMITED (GB) 2016-12-22 US disclosed
US-9447076-B2 Inhibitor of p38 map kinase RESPIVERT LTD. (GB) 2016-09-20 US disclosed
US-9447076-B2 Inhibitor of p38 map kinase RESPIVERT LTD. (GB) 2016-09-20 US disclosed
WO-2015121444-A1 AROMATIC HETEROCYCLIC COMPOUNDS AS ANTIINFLAMMATORY COMPOUNDS RESPIVERT LIMITED (GB) 2015-08-20 WO disclosed
US-20150232450-A1 INHIBITOR OF p38 MAP KINASE RESPIVERT LIMITED (GB) 2015-08-20 US disclosed
US-20150232450-A1 INHIBITOR OF p38 MAP KINASE RESPIVERT LIMITED (GB) 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170182039-A1 INHIBITOR OF p38 MAP KINASE MAPK1, MAPKAPK2, MAP3K1 ALDH1A1 2697/4885LMNA 1566/4885HCK 274/4885
US-10815217-B2 Inhibitor of p38 MAP kinase MAPK1, MAPKAPK2, MAP3K1 ALDH1A1 2697/4885LMNA 1566/4885HCK 274/4885
US-20210179584-A1 INHIBITOR OF p38 MAP KINASE MAPK1, MAPKAPK2, MAPK10 ALDH1A1 1810/4885LMNA 3181/4885HCK 812/4885
US-20160368896-A1 INHIBITOR OF p38 MAP KINASE MAPK1, MAPK4, MAPK8 ALDH1A1 2523/4885LMNA 2165/4885HCK 678/4885
US-11634406-B2 Inhibitor of p38 MAP kinase MAPK1, MAPKAPK2, MAPK10 ALDH1A1 1810/4885LMNA 3181/4885HCK 812/4885
US-20150232450-A1 INHIBITOR OF p38 MAP KINASE MAPK1, MAPKAPK2, MAPK10 ALDH1A1 1810/4885LMNA 3181/4885HCK 812/4885
US-20190092752-A1 INHIBITOR OF p38 MAP KINASE MAPK1, MAPKAPK2, MAP3K1 ALDH1A1 2697/4885LMNA 1566/4885HCK 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.